These are all valid points.
If I were Linda, and I had two companies I was invested in, that were linked at the hip, so to say, I'd try to look out for both of them.
Now, whatever the price is that NWBO (our company) is paying Cognate (more Linda's company, a private company), when the price is negotiated for the vaccine, it establishes what FMV is for this vaccine - as I don't know of any other company making vaccines like this at this time. And if I were Linda, I'd make sure the negotiated price worked out well for both of my companies.
Perhaps another company will come along and, after L is approved, and perhaps Direct is close to approval (or approved), will offer the product for less to NWBO. Perhaps Cognate will offer a significantly lower price for making the vaccine because the volume has increased, and NWBO will decline the offer because Cognate is now providing the product for a competitive price. But at this time, other than hiring a CFO to negotiate with Cognate (and Linda) for a FMP, we are stuck with this company that appears to be delivering the product in a manner that Germany and England find acceptable at this time. What more can be done?
Market Data 
Markets 
AI
